1
|
Czerniel J, Gostyńska A, Jańczak J, Stawny M. A critical review of the novelties in the development of intravenous nanoemulsions. Eur J Pharm Biopharm 2023; 191:36-56. [PMID: 37586663 DOI: 10.1016/j.ejpb.2023.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Revised: 07/10/2023] [Accepted: 08/12/2023] [Indexed: 08/18/2023]
Abstract
Nanoemulsions have gained increasing attention in recent years as a drug delivery system due to their ability to improve the solubility and bioavailability of poorly water-soluble drugs. This systematic review aimed to collect and critically analyze recent novelties in developing, designing, and optimizing intravenous nanoemulsions appearing in articles published between 2017 and 2022. The applied methodology involved searching two electronic databases PubMed and Scopus, using the keyword "nanoemulsion" in combination with "intravenous" or "parenteral". The resulting original articles were classified by the method of preparation into different categories. An overview of the current methods used for the preparation of such formulations, including high- and low-energy emulsification, was provided. The advantages and disadvantages of these methods were discussed, as well as their potential impact on the properties of the developed intravenous nanoemulsions. The problem of inconsistency in intravenous nanoemulsion terminology may lead to misunderstandings and misinterpretations of their properties and applications was also undertaken. Finally, the regulatory aspects of intravenous nanoemulsions, the state of the art in the field of intravenous emulsifiers, and the future perspectives were presented.
Collapse
Affiliation(s)
- Joanna Czerniel
- Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 6 Grunwaldzka, 60 - 780 Poznan, Poland
| | - Aleksandra Gostyńska
- Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 6 Grunwaldzka, 60 - 780 Poznan, Poland.
| | - Julia Jańczak
- Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 6 Grunwaldzka, 60 - 780 Poznan, Poland
| | - Maciej Stawny
- Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 6 Grunwaldzka, 60 - 780 Poznan, Poland
| |
Collapse
|
2
|
Séguy L, Daressy F, Lahlil S, Corvaisier S, Dumontet V, Litaudon M, Apel C, Roussi F, Wiels J, Robert A, Groo AC, Malzert-Fréon A. In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration. Int J Pharm 2023; 630:122433. [PMID: 36436745 DOI: 10.1016/j.ijpharm.2022.122433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 11/18/2022] [Accepted: 11/19/2022] [Indexed: 11/27/2022]
Abstract
MCL-1, an anti-apoptotic member of the BCL-2 protein family, is overexpressed in many types of cancer and contributes to chemotherapy resistance. The drimane derivative NA1-115-7 is a natural compound isolated from Zygogynum pancheri that can be considered as a very promising lead for treating MCL-1-dependent hematological malignancies. As this drug suffers from low stability in acidic conditions and poor aqueous solubility, we evaluated the potential oral use of NA1-115-7 by encapsulating it in lipid nanoemulsions (NA-NEs) prepared by spontaneous emulsification. NA-NEs showed a particle size of 41.9 ± 2.2 nm, PDI of 0.131 ± 0.016, zeta potential of -5.8 ± 3.4 mV, encapsulation efficiency of approximately 100 % at a concentration of 24 mM. The stability of NA-1-115-7 was sixfold higher than that of the unencapsulated drug in simulated gastric fluid. NA-NEs significantly restored apoptosis and halved the effective doses of NA1-115-7 on BL2, a Burkitt lymphoma cell line, without toxicity in normal cells. Such a drug-delivery system appears to be particularly interesting for the oral administration of NA1-115-7, as it improves its solubility and stability, as well as efficacy, by reducing the therapeutic dose, making it possible to further consider in-vivo studies of this promising drug in BL2 xenografted mice.
Collapse
Affiliation(s)
- Line Séguy
- Normandie Univ, UNICAEN, CERMN, 14000 Caen, France
| | - Florian Daressy
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France; UMR 9018 CNRS, Université Paris-Saclay, Gustave Roussy, 94805 Villejuif, France
| | - Sophia Lahlil
- UMR 9018 CNRS, Université Paris-Saclay, Gustave Roussy, 94805 Villejuif, France
| | | | - Vincent Dumontet
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Marc Litaudon
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Cécile Apel
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Fanny Roussi
- Institut de Chimie des Substances Naturelles, CNRS, UPR2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Joëlle Wiels
- UMR 9018 CNRS, Université Paris-Saclay, Gustave Roussy, 94805 Villejuif, France
| | - Aude Robert
- UMR1279 INSERM, Université Paris-Saclay, Gustave Roussy, 94805 Villejuif Cedex, France
| | | | | |
Collapse
|
3
|
Hosny KM, Sindi AM, Alkhalidi HM, Kurakula M, Hassan AH, Bakhaidar RB, Abualsunun WA, Almehmady AM, Khames A, Rizg WY, Khallaf RA, Alruwaili NK, Alhakamy NA. Development of omega-3 loxoprofen-loaded nanoemulsion to limit the side effect associated with NSAIDs in treatment of tooth pain. Drug Deliv 2021; 28:741-751. [PMID: 33840320 PMCID: PMC8057080 DOI: 10.1080/10717544.2021.1909179] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The majority of newly developed drugs need to be incorporated with delivery systems to maximize their effect and minimize side effects. Nanoemulsions (NEs) are one type of delivery system that helps to improve the solubility and dissolution of drugs, attempting to enhance their bioavailability and onset of action. The objective of this investigation was to develop an omega-3 oil-based NE loaded with loxoprofen (LXP) to enhance its dissolution, in vitro release, and mucosal penetration and decrease its mucosal ulcerative effects when applied in an oral treatment. LXP-loaded NEs were formulated with varying levels of omega-3 oil (10–30%), surfactant polyoxyethylene-C21-ethers (laureth-21) (40–60%), and co-surfactant polyethylene glycol-40 hydrogenated castor oil (HCO-40) (30–50%) using an extreme vertices mixture design. The developed NEs were characterized for globule size and drug loading capacity. The optimal formulation was tested for in vitro drug release, ex vivo permeation, and ulcer index value. The developed NE acquired a globule size ranging 71–195 nm and drug loading capacity of 43–87%. Considering the results of the in vitro release study, the optimized NE formulation achieved 2.45-fold and 2-fold increases in drug permeation across tested mucosa compared to a marketed tablet and drug aqueous dispersion, respectively. Moreover, the optimum NE exhibited the best ulcer index in comparison to drug aqueous suspension and different formulations when tested in rats. Overall, this research highlights the capacity of NEs to deliver LXP with enhanced solubility, drug release, and permeation while effectively protecting the application site from side effects of the model drug.
Collapse
Affiliation(s)
- Khaled M Hosny
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.,Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Amal M Sindi
- Oral Diagnostic Science Department, Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Hala M Alkhalidi
- Department of Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Mallesh Kurakula
- Department of Biomedical Engineering, The Herff College of Engineering, Memphis, TN, USA
| | - Amira H Hassan
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
| | - Rana B Bakhaidar
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Walaa A Abualsunun
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Alshaimaa M Almehmady
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Ahmed Khames
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.,Department of Pharmaceutics and Pharmacy Technology, College of Pharmacy, Taif University, Taif, Kingdom of Saudi Arabia
| | - Waleed Y Rizg
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.,Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Rasha A Khallaf
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
| | - Nabil K Alruwaili
- Department of Pharmaceutics, Faculty of Pharmacy, Jouf University, Skaka, Saudi Arabia
| | - Nabil A Alhakamy
- Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.,Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia
| |
Collapse
|
4
|
Voisin-Chiret AS. Meet Our Editorial Board Member. Anticancer Agents Med Chem 2021. [DOI: 10.2174/187152062104201224090951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
5
|
Design of Non-Haemolytic Nanoemulsions for Intravenous Administration of Hydrophobic APIs. Pharmaceutics 2020; 12:pharmaceutics12121141. [PMID: 33255606 PMCID: PMC7760703 DOI: 10.3390/pharmaceutics12121141] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 11/06/2020] [Accepted: 11/19/2020] [Indexed: 02/07/2023] Open
Abstract
Among advanced formulation strategies, nanoemulsions are considered useful drug-delivery systems allowing to improve the solubility and the bioavailability of lipophilic drugs. To select safe excipients for nanoemulsion formulation and to discard any haemolytic potential, an in vitro miniaturized test was performed on human whole blood. From haemolysis results obtained on eighteen of the most commonly used excipients, a medium chain triglyceride, a surfactant, and a solubilizer were selected for formulation assays. Based on a design of experiments and a ternary diagram, the feasibility of nanoemulsions was determined. The composition was defined to produce monodisperse nanodroplets with a diameter of either 50 or 120 nm, and their physicochemical properties were optimized to be suitable for intravenous administration. These nanoemulsions, stable over 21 days in storage conditions, were shown to be able to encapsulate with high encapsulation efficiency and high drug loading, up to 16% (w/w), two water practically insoluble drug models: ibuprofen and fenofibrate. Both drugs may be released according to a modulable profile in sink conditions. Such nanoemulsions appear as a very promising and attractive strategy for the efficient early preclinical development of hydrophobic drugs.
Collapse
|
6
|
Groo AC, Hedir S, Since M, Brotin E, Weiswald LB, Paysant H, Nee G, Coolzaet M, Goux D, Delépée R, Freret T, Poulain L, Voisin-Chiret AS, Malzert-Fréon A. Pyridoclax-loaded nanoemulsion for enhanced anticancer effect on ovarian cancer. Int J Pharm 2020; 587:119655. [PMID: 32712252 DOI: 10.1016/j.ijpharm.2020.119655] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 06/26/2020] [Accepted: 07/13/2020] [Indexed: 01/22/2023]
Abstract
BACKGROUND Pyridoclax is an original lead, recently identified as very promising in treatment of chemoresistant ovarian cancers. To correct the unfavorable intrinsic physico-chemical properties of this BCS II drug, a formulation strategy was implied in the drug discovery step. Pyridoclax-loaded nanoemulsions (NEs) were developed to permit its preclinical evaluation. RESULTS The resulting nanoemulsions displayed a mean size of about 100 nm and a high encapsulation efficiency (>95%) at a drug loading of 2 wt%, enabling a 1,000-fold increase of the Pyridoclax apparent solubility. NEs have enabled a sustained release of the drug as assayed by a dialysis bag method. In addition, anti-tumor effects of the Pyridoclax-loaded nanoemulsions (PNEs) showed a 2.5-fold higher activity on chemoresistant ovarian cancer cells than free Pyridoclax. This effect was confirmed by a drastic increase of caspase 3/7 activation from 10 µM PNEs, as newly objectified by real time apoptose imaging. The Pyridoclax bioavailability was kept unchanged after encapsulation in nanoemulsions as determined in a mice model after oral administration. CONCLUSION Thus, NEs should permit valuable Pyridoclax oral administration, and valorization of this promising anticancer drug by maintaining its original anticancer activity, and by reducing the Pyridoclax therapeutic concentration.
Collapse
Affiliation(s)
- A C Groo
- Normandie Univ, UNICAEN, CERMN, 14000 Caen, France.
| | - S Hedir
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France
| | - M Since
- Normandie Univ, UNICAEN, CERMN, 14000 Caen, France
| | - E Brotin
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France; Normandie Univ, UNICAEN, SF4206 Icore, ImpedanCELL Platform, 14000 Caen, France
| | - L-B Weiswald
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France
| | - H Paysant
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France
| | - G Nee
- Normandie Univ, UNICAEN, Inserm U1075, Comete, GIP CYCERON, 14000 Caen, France
| | - M Coolzaet
- Normandie Univ, UNICAEN, Inserm U1075, Comete, GIP CYCERON, 14000 Caen, France
| | - D Goux
- Normandie Univ, UNICAEN, CMAbio(3), SF4206 Icore, 14000 Caen, France
| | - R Delépée
- Normandie Univ, UNICAEN, PRISMM Platform, SF4206 ICORE, Comprehensive Cancer Center F. Baclesse, 14000 Caen, France
| | - T Freret
- Normandie Univ, UNICAEN, Inserm U1075, Comete, GIP CYCERON, 14000 Caen, France
| | - L Poulain
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE "Interdisciplinary Research Unit for Cancer Prevention and Treatment", 14000 Caen, France; UNICANCER, Cancer Centre F. Baclesse, 14076 Caen, France
| | | | | |
Collapse
|
7
|
Anuar N, Sabri AH, Bustami Effendi TJ, Abdul Hamid K. Development and characterisation of ibuprofen-loaded nanoemulsion with enhanced oral bioavailability. Heliyon 2020; 6:e04570. [PMID: 32775730 PMCID: PMC7394867 DOI: 10.1016/j.heliyon.2020.e04570] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Revised: 07/14/2020] [Accepted: 07/23/2020] [Indexed: 02/06/2023] Open
Abstract
Lipophilic compounds constitute a majority of therapeutics in the pipeline of drug discovery. Despite possessing enhanced efficacy and permeability, some of these drugs suffer poor solubility necessitating the need of a suitable drug delivery system. Nanoemulsion is a drug delivery system that provides enhanced solubility for poorly soluble drugs in an attempt to improve the oral bioavailability. The purpose of this study is to develop a nanoemulsion system using ibuprofen as a model drug in order to investigate the potential of this colloidal system to enhance the absorption of poorly water-soluble drugs. Ibuprofen loaded-nanoemulsion with different drug concentrations (1.5, 3 and 6% w/w) were formulated from olive oil, sucrose ester L-1695 and glycerol using D-phase emulsification technique. A pseudoternary phase diagram was utilised to identify the optimal excipient composition to formulate the nanoemulsion system. In vitro diffusion chamber studies using rodent intestinal linings highlighted improved absorption profile when ibuprofen was delivered as nanoemulsion in comparison to microemulsions and drug-in-oil systems. This was further corroborated by in vivo studies using rat model that highlighted a two-fold increase in ibuprofen absorption when the drug was administered as a nanoemulsion relative to drug-in-oil system. On the other hand, when ibuprofen was administered as microemulsions, only a 1.5-fold increase in absorption was observed relative to drug-in-oil system. Thus, this study highlights the potential of using nanoemulsion as a drug delivery system to enhance the oral bioavailability of hydrophobic drugs.
Collapse
Affiliation(s)
- Nurfazreen Anuar
- Department of Pharmaceutics, Faculty of Pharmacy, Universiti Teknologi MARA, Cawangan Selangor, 42300 Puncak Alam, Selangor, Malaysia
| | - Akmal H. Sabri
- Advanced Materials and Healthcare Technologies Group, School of Pharmacy, The University of Nottingham, NG7 2RD, Nottingham, UK
| | - Tommy Julianto Bustami Effendi
- Department of Pharmaceutics, Faculty of Pharmacy, Universiti Teknologi MARA, Cawangan Selangor, 42300 Puncak Alam, Selangor, Malaysia
| | - Khuriah Abdul Hamid
- Department of Pharmaceutics, Faculty of Pharmacy, Universiti Teknologi MARA, Cawangan Selangor, 42300 Puncak Alam, Selangor, Malaysia
| |
Collapse
|
8
|
De Pascale M, Iacopetta D, Since M, Corvaisier S, Vie V, Paboeuf G, Hennequin D, Perato S, De Giorgi M, Sinicropi MS, Sopkova-De Oliveira Santos J, Voisin-Chiret AS, Malzert-Freon A. Synthesis of Pyridoclax Analogues: Insight into Their Druggability by Investigating Their Physicochemical Properties and Interactions with Membranes. ChemMedChem 2020; 15:136-154. [PMID: 31743599 DOI: 10.1002/cmdc.201900542] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Revised: 10/30/2019] [Indexed: 12/20/2022]
Abstract
Pyridoclax is considered a promising anticancer drug, acting as a protein-protein interaction disruptor, with potential applications in the treatment of ovarian, lung, and mesothelioma cancers. Eighteen sensibly selected structural analogues of Pyridoclax were synthesized, and their physicochemical properties were systematically assessed and analyzed. Moreover, considering that drug-membrane interactions play an essential role in understanding the mode of action of a given drug and its eventual toxic effects, membrane models were used to investigate such interactions in bulk (liposomes) and at the air-water interface. The measured experimental data on all original oligopyridines allowed the assessment of relative differences in terms of physicochemical properties, which could be determinant for their druggability, and hence for drug development.
Collapse
Affiliation(s)
| | - Domenico Iacopetta
- Department of Pharmacy Health and Nutritional Sciences, University of Calabria, 87036, Arcavacata di Rende, Italy
| | - Marc Since
- Normandie Univ, UniCaen, CERMN, 14000, Caen, France
| | | | - Véronique Vie
- Département Matière Molle BioMolécules aux Interfaces Fluides IPR, UR1, Campus de Beaulieu, 35042, Rennes Cedex, France
| | - Gilles Paboeuf
- Département Matière Molle BioMolécules aux Interfaces Fluides IPR, UR1, Campus de Beaulieu, 35042, Rennes Cedex, France
| | | | - Serge Perato
- Normandie Univ, UniCaen, CERMN, 14000, Caen, France
| | | | - Maria Stefania Sinicropi
- Department of Pharmacy Health and Nutritional Sciences, University of Calabria, 87036, Arcavacata di Rende, Italy
| | | | | | | |
Collapse
|
9
|
An overview of techniques for multifold enhancement in solubility of poorly soluble drugs. CURRENT ISSUES IN PHARMACY AND MEDICAL SCIENCES 2019. [DOI: 10.2478/cipms-2019-0035] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
Poor water solubility of newly discovered compounds has become the most common challenge in the drug development process. Indeed, poor solubility is considered as the root cause of failure of drug during drug development phases. Moreover, it has also been reported to be the main reason for bioavailability issues such as poor, inconsistent, incomplete and highly variable bioavailability of the marketed products. As per an estimate, approximately 90% of drug molecules suffer with poor water solubility at early stage and approximately 40% of the marketed drugs have bioavailability problems mainly due to poor water solubility. Solubility enhancement of the newly discovered compounds is primary research area for the pharmaceutical industries and research institutions. The conventional techniques to improve aqueous solubility of drugs employ salt formation, prodrug formation, co-crystallization, complexation, amorphous solid dispersion and use of co-solvent, surfactants or hydrotropic agents. Current advancement in the science and technology has enabled the use of relatively new techniques under the umbrella of nanotechnology. These include the development of nanocrystals, nanosuspensions, nanoemulsions, microemulsions, liposomes and nanoparticles to enhance the solubility. This review focuses on the conventional and current approaches of multifold enhancement in the solubility of poorly soluble marketed drugs, including newly discovered compounds.
Collapse
|
10
|
Microplate assay for lipophilicity determination using intrinsic fluorescence of drugs: Application to a promising anticancer lead, pyridoclax. Eur J Pharm Sci 2019; 131:75-83. [DOI: 10.1016/j.ejps.2019.02.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2018] [Revised: 02/01/2019] [Accepted: 02/07/2019] [Indexed: 11/18/2022]
|
11
|
Nanoemulsions in CNS drug delivery: recent developments, impacts and challenges. Drug Discov Today 2019; 24:1104-1115. [PMID: 30914298 DOI: 10.1016/j.drudis.2019.03.021] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 03/03/2019] [Accepted: 03/20/2019] [Indexed: 02/06/2023]
Abstract
Despite enormous efforts, treatment of CNS diseases remains challenging. One of the main issues causing this situation is limited CNS access for the majority of drugs used as part of the therapeutic regimens against life-threatening CNS diseases. Regarding the inarguable position of the nanocarrier systems in neuropharmacokinetic enhancement of the CNS drugs, this review discusses the latest findings on nanoemulsions (NEs) as one of the most promising candidates of this type, to overcome the challenges of CNS drug delivery. Future development of NE-based CNS drug delivery needs to consider so many aspects not only from a physicochemical point of view but also related to the biointerface of these very small droplets before achieving clinical value.
Collapse
|
12
|
Anzilaggo D, O’Reilly Beringhs A, Pezzini BR, Sonaglio D, Stulzer HK. Liquisolid systems: Understanding the impact of drug state (solution or dispersion), nonvolatile solvent and coating material on simvastatin apparent aqueous solubility and flowability. Colloids Surf B Biointerfaces 2019; 175:36-43. [DOI: 10.1016/j.colsurfb.2018.11.044] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Revised: 11/06/2018] [Accepted: 11/19/2018] [Indexed: 10/27/2022]
|
13
|
Hedir S, De Giorgi M, Fogha J, De Pascale M, Weiswald LB, Brotin E, Marekha B, Denoyelle C, Denis C, Suzanne P, Gautier F, Juin P, Ligat L, Lopez F, Carlier L, Legay R, Bureau R, Rault S, Poulain L, Oliveira Santos JSD, Voisin-Chiret AS. Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode. Eur J Med Chem 2018; 159:357-380. [PMID: 30308410 DOI: 10.1016/j.ejmech.2018.10.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Revised: 09/28/2018] [Accepted: 10/01/2018] [Indexed: 11/18/2022]
Abstract
Protein-protein interactions are attractive targets because they control numerous cellular processes. In oncology, apoptosis regulating Bcl-2 family proteins are of particular interest. Apoptotic cell death is controlled via PPIs between the anti-apoptotic proteins hydrophobic groove and the pro-apoptotic proteins BH3 domain. In ovarian carcinoma, it has been previously demonstrated that Bcl-xL and Mcl-1 cooperate to protect tumor cells against apoptosis. Moreover, Mcl-1 is a key regulator of cancer cell survival and is a known resistance factor to Bcl-2/Bcl-xL pharmacological inhibitors making it an attractive therapeutic target. Here, using a structure-guided design from the oligopyridine lead Pyridoclax based on Noxa/Mcl-1 interaction we identified a new derivative, active at lower concentration as compared to Pyridoclax. This new derivative selectively binds to the Mcl-1 hydrophobic groove and releases Bak and Bim from Mcl-1 to induce cell death and sensitize cancer cells to Bcl-2/Bcl-xL targeting strategies.
Collapse
Affiliation(s)
- Siham Hedir
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE «Interdisciplinary Research Unit for Cancer Prevention and Treatment», Biology and Innovative Therapeutics for Ovarian Cancers Group (BioTICLA), Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France; UNICANCER, Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France
| | - Marcella De Giorgi
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Jade Fogha
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Martina De Pascale
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Louis-Bastien Weiswald
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE «Interdisciplinary Research Unit for Cancer Prevention and Treatment», Biology and Innovative Therapeutics for Ovarian Cancers Group (BioTICLA), Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France; UNICANCER, Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France
| | - Emilie Brotin
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE «Interdisciplinary Research Unit for Cancer Prevention and Treatment», Biology and Innovative Therapeutics for Ovarian Cancers Group (BioTICLA), Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France; UNICANCER, Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France
| | - Bogdan Marekha
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Christophe Denoyelle
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE «Interdisciplinary Research Unit for Cancer Prevention and Treatment», Biology and Innovative Therapeutics for Ovarian Cancers Group (BioTICLA), Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France; UNICANCER, Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France
| | - Camille Denis
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Peggy Suzanne
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Fabien Gautier
- Team 8 "Stress adaptation and tumor escape", CRCINA, UMR 1232 INSERM, Université de Nantes, Université d'Angers, Institut de Recherche en Santé-Université de Nantes, Nantes, France; ICO site René Gauducheau, Boulevard Jacques Monod, Saint Herblain, 44805, France
| | - Philippe Juin
- Team 8 "Stress adaptation and tumor escape", CRCINA, UMR 1232 INSERM, Université de Nantes, Université d'Angers, Institut de Recherche en Santé-Université de Nantes, Nantes, France; ICO site René Gauducheau, Boulevard Jacques Monod, Saint Herblain, 44805, France
| | - Laetitia Ligat
- INSERM UMR1037-Plateforme Protéomique-Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse, 2 avenue Hubert Curien, 31100 Toulouse, France; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, 31000 Toulouse, France
| | - Frédéric Lopez
- INSERM UMR1037-Plateforme Protéomique-Pôle Technologique du Centre de Recherches en Cancérologie de Toulouse, 2 avenue Hubert Curien, 31100 Toulouse, France; Université Toulouse III-Paul Sabatier, UMR1037 CRCT, 31000 Toulouse, France
| | - Ludovic Carlier
- Sorbonne Université, Ecole normale supérieure, PSL University, CNRS, Laboratoire des Biomolécules (LBM), 75005 Paris, France
| | - Rémi Legay
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Ronan Bureau
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Sylvain Rault
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France
| | - Laurent Poulain
- Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE «Interdisciplinary Research Unit for Cancer Prevention and Treatment», Biology and Innovative Therapeutics for Ovarian Cancers Group (BioTICLA), Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France; UNICANCER, Centre de Lutte Contre le Cancer F. Baclesse, 3 avenue du Général Harris, 14076, Caen, France.
| | - Jana Sopková-de Oliveira Santos
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France.
| | - Anne Sophie Voisin-Chiret
- Normandie Univ, UNICAEN, EA 4258 CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) - FR CNRS INC3M, Caen, France.
| |
Collapse
|
14
|
Sun W, Pan B. Effect of micro-environment modification and polymer type on the in-vitro dissolution behavior and in-vivo performance of amorphous solid dispersions. Eur J Pharm Sci 2017; 104:240-254. [DOI: 10.1016/j.ejps.2017.04.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Revised: 04/12/2017] [Accepted: 04/12/2017] [Indexed: 11/30/2022]
|
15
|
Zhang Y, Zhang D, Zhang Y, Liu L, Zhang X, Zhang L, Zhang Y, Chang L, Fan Q, Zhang Y, Xi J, Zhang Q. Improving solubility and avoiding hygroscopicity of tetrahydroberberine by forming hydrochloride salts by introducing solvents: [HTHB]Cl, [HTHB]Cl·CH3OH and [HTHB]Cl·CH3COOH. NEW J CHEM 2017. [DOI: 10.1039/c7nj02423a] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Improving the solubility of tetrahydroberberine by forming hydrochloride salts and avoiding the hygroscopicity.
Collapse
Affiliation(s)
- Yunan Zhang
- College of Pharmacy
- Jiamusi University
- Jiamusi
- China
| | - Dajun Zhang
- College of Pharmacy
- Jiamusi University
- Jiamusi
- China
| | - Yu Zhang
- College of Pharmacy
- Jiamusi University
- Jiamusi
- China
| | - Lixin Liu
- College of Pharmacy
- Jiamusi University
- Jiamusi
- China
| | - Xuesong Zhang
- First Affiliated Hospital
- Jiamusi University
- Jiamusi
- China
| | - Lei Zhang
- College of Pharmacy
- Jiamusi University
- Jiamusi
- China
| | - Yunjie Zhang
- College of Pharmacy
- Jiamusi University
- Jiamusi
- China
| | - Liang Chang
- College of Pharmacy
- Jiamusi University
- Jiamusi
- China
| | | | | | - Jiaming Xi
- College of Pharmacy
- Jiamusi University
- Jiamusi
- China
| | - Qiang Zhang
- School of Public Health
- Jiamusi University
- Jiamusi
- China
| |
Collapse
|